Good Therapeutics

We are fortunate to have an experienced and engaged group of investors, most of whom also participated in our predecessor company Good Therapeutics, who share our excitement and fully grasp the potential of our technology. We are creating a new class of regulated protein therapeutics designed to deliver potent biological activity only where needed. We are currently focused on developing regulated cytokines with context-dependent activity to treat cancer. Currently, we are focused on the development of context-dependent cytokine-based therapeutics designed to bolster the anti-tumor immune response. They've provided unwavering support and insight, which has been crucial on our scientific path to discovery. John Mulligan is a scientist and executive with 30 years of experience in research management, drug discovery, technology innovation and company formation. Diane Hollenbaugh is a drug discovery scientist and executive with more than 25 years of experience in biologicals research and discovery, and early development. Neela Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation.